H.C. Wainwright lowered the firm’s price target on Y-mAbs Therapeutics (YMAB) to $12 from $22 and keeps a Buy rating on the shares. The firm is pushing back the time to U.S. market entry for naxitamab in the first-line high-risk NB setting to 2028 and removed CD38-SADA revenues from its valuation while also pushing back the time to U.S. market entry for GD2-SADA to 2028, driving its price target reduction.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Positive Outlook on Y-Mabs Therapeutics Despite Adjusted Price Target, Driven by Promising Radiopharmaceutical Platform
- Y-mAbs Therapeutics price target lowered to $12 from $14 at BofA
- Y-mAbs Therapeutics price target lowered to $18 from $21 at Truist
- Y-mAbs Therapeutics price target lowered to $7 from $11 at Morgan Stanley
- Y-mAbs Therapeutics price target lowered to $21 from $23 at Oppenheimer